Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. [electronic resource]
Producer: 20151105Description: 1702-12 p. digitalISSN:- 1476-5551
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis -- drug effects
- Bridged Bicyclo Compounds, Heterocyclic -- pharmacology
- Cell Proliferation -- drug effects
- Cyclic N-Oxides
- Drug Synergism
- Female
- Humans
- Immunoenzyme Techniques
- Indolizines
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Myeloid Cell Leukemia Sequence 1 Protein -- antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Pyridinium Compounds -- pharmacology
- RNA, Messenger -- genetics
- Real-Time Polymerase Chain Reaction
- Reverse Transcriptase Polymerase Chain Reaction
- Sulfonamides -- pharmacology
- Tissue Array Analysis
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.